'Drug-only' glycopyrronium bromide shows Phase II promise in COPD
This article was originally published in Scrip
Executive Summary
Prosonix, a tiny UK company developing a 'drug-only' glycopyrronium bromide product has obtained positive top-line results from a Phase II study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).